EUCTR2006-006739-36-FR进行中（未招募）1 期
A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancer
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be eligible to participate in the study if they meet all of the criteria listed below.
- •1. Ethical
- •Competent to comprehend, sign, and date an IEC-approved informed consent form.
- •2. Demographic
- •Of either gender and aged 18 years or more.
- •3. Disease-related
- •Diagnosed with histologically- or cytologically-confirmed metastatic adenocarcinoma of the colon and/or rectum.
- •Measurable disease according to modified RECIST guidelines. All sites of disease must have been evaluated within 28 days of initiating study treatment, and diagnosed by the investigator.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- •Have available paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour.
- •4. Laboratory
- •-Haematologic function, as follows (within seven days prior to initiating study treatment):
- •Absolute neutrophil count (ANC) = 1.5 x 109/L.
- •Platelet count =100 x 109/L.
- •Haemoglobin =10 g/dL.
- •-Renal function, as follows (within seven days prior to initiating study treatment):
- •Creatinine =1.5 mg/dL.
- •-Hepatic function, as follows (within seven days prior to initiating study treatment):
- •Aspartate aminotransferase (AST) =3 x ULN (if liver metastases = 5 x ULN).
- •Alanine aminotransferase (ALT) =3 x ULN (if liver metastases = 5 x ULN).
- •Bilirubin = 2 x ULN.
- •-Metabolic function, as follows (within seven days prior to initiating study treatment):
- •Magnesium = lower limit of normal.
- •Calcium = lower limit of normal.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any patient exhibiting any of the criteria listed below will be excluded from the study:
- •1. Disease Related
- •Central nervous system metastases (Exception: subjects who have been treated, have asymptomatic central nervous system metastases, and have been off steroids for at least 30 days before initiating study treatment are eligible).
- •2. Therapies
- •Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months prior to initiating study treatment.
- •Prior anti-EGFr antibody therapy (e.g.: cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g.: erlotinib).
- •Prior radiotherapy within 14 days prior to screening, and for which all signs of early radiological toxicity have not abated.
- •3. General
- •Significant cardiovascular disease including unstable angina or myocardial infarction within six months before initiating study treatment or a history of ventricular arrhythmia.
- •History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan.
- •Treatment for systemic infection within 14 days before initiating study treatment.
- •Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day).
- •History of Gilbert’s syndrome or dihydropyrimidine deficiency.
- •History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.
- •Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection.
- •Any co-morbid disease that would increase risk of toxicity.
- •Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.
- •Any investigational agent within 30 days before initiation of study treatment.
- •Must not have had a major surgical procedure within 28 days prior to initiation of study treatment.
- •Subject who is pregnant or breast-feeding.
- •Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods (e.g. diaphragm plus condom) during the course of the study and for six months after the last study drug administration for women, and one month for men.
- •Subject unwilling or unable to comply with study requirements.
研究者
相似试验
进行中（未招募）
不适用
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerPatients with metastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006739-36-SEAmgen Inc150
进行中（未招募）
不适用
A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal CancerPatients with metastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2006-006739-36-ATAmgen Inc150
进行中（未招募）
不适用
A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal CancerPatients with metastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2006-006739-36-DEAmgen Inc150
进行中（未招募）
不适用
A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal CancerPatients with metastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2006-006739-36-BEAmgen Inc150
进行中（未招募）
1 期
An open label multicentric phase II study of Panitumumab (Vectibix®) in cutaneous squamous cell carcinoma (SCC) - PASCECutaneous Squamous Cell Carcinoma (SCC)MedDRA version: 12.1Level: LLTClassification code 10041823Term: Squamous cell carcinomaMedDRA version: 12.1Level: PTClassification code 10041823Term: Squamous cell carcinomaEUCTR2009-015237-76-BECentre du Cancer des Cliniques Universitaires Saint-Luc17